Clinical Trial Update: Neoadjuvant Intralesional Injection of Talimogene Laherparepvec [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating intralesional talimogene laherparepvec for soft tissue sarcoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)

Snippet

Sponsor: John Rieth | Conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue | Phase 2 | Status: ACTIVE_NOT_RECRUITING